Connect with us
European Gaming Congress 2024

Artificial Intelligence

Cerebrospinal Fluid Management Market Size, $2.61Bn by 2028 Lead by CSF Shunts, 5.3% CAGR – Exclusive Research Report by The Insight Partners

Published

on

New York, Jan. 24, 2022 (GLOBE NEWSWIRE) — According to our new research study on “Cerebrospinal Fluid Management Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Product (CSF Shunts and CSF Drainage Systems) and End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Neurological Centers)”, published by The Insight Partners. The cerebrospinal fluid management market growth is driven by the increasing prevalence of hydrocephalus and the subsequent increase in the number of shunting procedures and the growing geriatric population.

Get Exclusive Sample Pages of Cerebrospinal Fluid Management Market Size – COVID-19 Impact and Global Analysis with Strategic Insights at https://www.theinsightpartners.com/sample/TIPRE00004182/

Report Coverage Details
Market Size Value in US$ 1.82 Billion in 2021
Market Size Value by US$ 2.61 Billion by 2028
Growth rate CAGR of 5.3% from 2021 to 2028
Forecast Period 2021-2028
Base Year 2021
No. of Pages 189
No. Tables 111
No. of Charts & Figures 75
Historical data available Yes
Segments covered Product and End User
Regional scope North America; Europe; Asia Pacific; Latin America; MEA
Country scope US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina
Report coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Cerebrospinal Fluid Management Market: Competition Landscape and Key Developments
Medtronic, Integra Life Sciences Corporation, DePuy Synthes, and Spiegelberg GmbH & Co. KG have implemented various inorganic developments, which have bought dynamic improvements in the cerebrospinal fluid management market. Several companies are adopting organic strategies such as product launch and expansion and inorganic growth strategies such as partnerships and collaboration. These growth strategies have aided the market players in expanding their business and enhancing their geographic presence. Additionally, market growth strategies such as acquisitions and partnerships helped strengthen their customer base and increase the product portfolio.

Inquiry Before Buying: https://www.theinsightpartners.com/inquiry/TIPRE00004182/

In December 2021, Spiegelberg Contract, along with Innovative Medcare PTY Ltd. located in Melbourne, Australia, joined the growing Spiegelberg family.

Advertisement
Stake.com

In May 2021, DePuy Synthes Products, Inc acquired the assets of Medical Enterprises Distribution, LLC, a privately-held developer of surgical impactor technology.

In April 2021, Medtronic plc and Surgical Theater announced a partnership to interface Surgical Theater’s SyncAR augmented reality (AR) technology with Medtronic’s StealthStation S8 surgical navigation system. This collaboration will enable neurosurgeons to use AR technology in real-time to enhance visualization during complex cranial procedures.

In November 2020, Medtronic plc announced that it had completed its friendly tender offer for France-based Medicrea International, a pioneer in the transformation of spinal surgery through artificial intelligence (AI), predictive modeling, and patient-specific implants. On July 15, 2020, the parties announced a friendly voluntary all-cash tender offer at the price of EUR 7.00 per Medicrea share.

In July 2019, Integra LifeSciences Holdings Corporation acquired Arkis Biosciences Inc. This privately-held company offers a portfolio of neurosurgical devices, including the CerebroFlo external ventricular drainage (EVD) catheter with Endexo technology, a permanent additive designed to reduce the potential for catheter obstruction due to thrombus formation.

Speak to Research Analyst: https://www.theinsightpartners.com/speak-to-analyst/TIPRE00004182/

Advertisement
Stake.com

Cerebrospinal Fluid Management: Key Insights – Impact of COVID-19 Pandemic
In North America, during the initial phase of the COVID-19 crisis, the demand for cerebrospinal fluid management was disrupted due to a temporary shift in the provision of healthcare services and the prolonged shutdown situation. Due to the pandemic situation in Europe, the hospitals in the region were severely affected. The increased pressure due to the growing rate of COVID-19 patients’ hospitalization led to the profiling of many hospitals and departments, including neurology clinics for treating patients with COVID-19. Consequently, it has been reported that many diagnostic and treatment procedures had been postponed, including as many as 2.3 million cancer surgeries. This was mainly due to the prevailing pandemic situation across the globe. Countries in Asia Pacific also faced similar scenarios, where the COVID-19 outbreak created an extraordinary emergency that significantly disrupted the provision of healthcare services. The restrictions on healthcare services have put the healthcare industry in a critical situation. For instance, the pandemic led the Japanese economy to contract by 29% annually. According to the International Council of Nurses, due to high virus transmission, the number of mortalities among health professionals in Brazil is higher than in other nations. As Brazil has many populated areas and regions with small houses with 6–7 people per house, the virus spread was like wildfire. Currently, the South and Central American countries are speedily increasing their clinical programs to fight against the pandemic. Thus, there was an unexpected decrease in the shunt surgeries during the pandemic, particularly in the types/numbers of revision surgeries performed. As a result, it was reported that the demand for CSF shunts decreased, owing to fewer surgical operations, creating a demand that is increasing at a decreasing rate (slower pace). This is expected to positively impact the cerebrospinal fluid management market over the forecast period.

Cerebrospinal Fluid Management Market: Segmental Overview
Based on end user, the cerebrospinal fluid management market is segmented into hospitals, clinics, ambulatory surgical centers, and neurological centers. The hospitals segment held the largest share of 44.83% in 2021 and is expected to retain its dominance during the forecast period. However, the clinics segment is estimated to register a CAGR of 5.2% during the forecast period. The clinics offer specialized services without admissions. The increasing number of clinics across the countries and the growing healthcare expenditures are likely to foster the overall market growth. Also, an increase in awareness regarding health problems and personalized services at clinics are supporting the market’s growth.

Buy Premium Copy of Cerebrospinal Fluid Management Market Size, Share, Revenue, Strategic Insights and Forecasts 2021-2028 Research Report at https://www.theinsightpartners.com/buy/TIPRE00004182/

The majority of the hospitals offer CSF management services under the insurance that enables patients to get their treatment done effectively and efficiently. Also, the majority of the hospitals worldwide are focusing on implementing neurological services to offer effective treatment outcomes over a range of diseases that drive the concerned industry. Thus, the hospitals segment is predicted to grow during the forecast period. Multi-center pediatric hospitals in India are using external ventricular devices that are playing an important role in driving the demand for cerebrospinal fluid management at present, and a similar trend is expected to continue over the forecast period.

Browse Adjoining Reports:

Advertisement
Stake.com

Neurosurgery Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Product Type (Neuro-Interventional Devices, Neurosurgical Navigation Systems, Neurostimulation Devices, CSF Management Devices, Others); Application (Brain Aneurysm, Tumor Resection, Traumatic Brain Injury, Hematoma, Others); End User (Hospitals, Specialty Clinics) and Geography

Neurosurgery Devices Market Forecast to 2028 – Covid-19 Impact and Global Analysis – By Product (Neurointerventional Devices, Neurostimulation Devices, Neurosurgical Navigation Systems, Neurosurgical Power Tools, CSF Management Tools, and Others), End User (Hospitals, Ambulatory Surgical Centers and Others) and Geography

Ventricular Drainage Sets Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Product Type (Ventricular Drainage Set, and Accessories); Application (Intraventricular Hemorrhage, Intracranial Hypertension, Hydrocephalus, CSF Infection, and Others); End Use (Hospitals, Ambulatory Surgical Centers, and Others), and Geography

Adult Neurosurgery Devices Market Forecast to 2028 – Covid-19 Impact and Global Analysis – by Type (Neuro Interventional Devices, Neuro Stimulation Devices, Neurosurgical Navigation Systems, Neurosurgical Power Tools, CSF Management Devices, Others); Application (Chronic Pain, Depression, Parkinson’s Disease, Ischemia, Others); End User (Hospitals, Ambulatory Surgery Centres, Others) and Geography

Equipment for Neurosurgery Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Equipment Type (Neuroendoscope, Stereotactic Systems, Aneurysm Clips, Neurostimulation Devices, Cerebrospinal Fluid Management Devices, Neurosurgical Evacuation Device, Neurosurgical Navigation Systems, Others); Surgery Type (Intracranial Surgery, Endonasal Neurosurgery, Spinal Surgery); End User (Hospitals, Ambulatory Surgical Centers) and Geography

Advertisement
Stake.com

Computational Fluid Dynamics (CFD) Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Deployment Model (Cloud-Based, On-Premise); End User (Automotive, Aerospace and Defense, Electrical and Electronics, Material and Chemical Processing, Others) and Geography

Magneto rheological fluid Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Base Fluid (Silicon Oil, Mineral Oil, Synthetic Hydrocarbon Oil, Paraffin Oil, Hydraulic Oil, Water, Others); Application (Automotive, Aerospace, Building and Construction, Military and Defense, Optics, Electrical and Electronics, Medical and Prosthetics, Robotics, Others) and Geography

Medical Peristaltic Pump Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Type (Low Pressure Pumps, High Pressure Pumps); Material (Silicone, Autoperene, Viton, Others); Application (IV Fluid Delivery, Blood Circulation, Others); End User (Hospitals, Diagnostic Labs, Academic and Research Institutes, Others)

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:

Advertisement
Stake.com

Contact Person: Sameer Joshi
E-mail: [email protected]
Phone: +1-646-491-9876
Press Release: https://www.theinsightpartners.com/pr/cerebrospinal-fluid-management-market
More Research: https://www.einpresswire.com/newsroom/the_insight_partners/

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Transforming Healthcare with AI: Yidu Tech’s Gong Rujing at Summer Davos

Published

on

transforming-healthcare-with-ai:-yidu-tech’s-gong-rujing-at-summer-davos

DALIAN, China, July 1, 2024 /PRNewswire/ — “AI in healthcare is extremely challenging. For companies, it requires not only solving scientific problems but also understanding AI technology and respecting the complexity of the healthcare industry.” At the 15th Annual Meeting of the New Champions, also known as Summer Davos, Ms. Gong Rujing (Yingying), Chairwoman and Founder of Yidu Tech, was invited as a distinguished representative of the healthcare technology sector. She shared her unique insights into the future of AI in healthcare during the thematic dialogue on “Healthcare Analytics, Not Moving Fast Enough.”

This year marks the 10th anniversary of Yidu Tech and Ms. Gong Rujing’s decade-long dedication to the healthcare industry. From the inception of her entrepreneurial journey 10 years ago, she has been driven by the mission to leverage the power of technology to deliver precise healthcare to every individual.
Ms. Gong described the past decade as a journey filled with miracles and achievements. During this period, Yidu Tech has progressively established close collaborations with key stakeholders in the healthcare industry, including government agencies, hospitals, pharmaceutical companies, insurance firms, experts, and clinicians. As of March 31, 2024, Yidu Tech’s “AI Medical Brain” YiduCore has been authorized to process and analyze over 5 billion medical records, covering more than 2,500 hospitals.
In AI-powered clinical research, Yidu Tech has supported researchers and clinicians in producing over 240 high-level papers, accelerating the application of research outcomes. Additionally, Yidu Tech provides clinical trial services to globally renowned pharmaceutical companies, helping them optimize trial processes, reduce costs, and bring new drugs to market more swiftly, ultimately benefiting patients. In healthcare management, Yidu Tech’s AI technology plays a crucial role by analyzing vast amounts of medical data to provide comprehensive decision support to healthcare administrators, helping them optimize resource allocation and improve service efficiency.
“We are now entering a new era of AI technology.” The development of large language model technologies has opened up new possibilities across various industries. Yidu Tech has independently developed a large language model specific to the medical field and is advancing its application across the entire healthcare industry chain. The goal is to promote further progress and innovation through new AI technologies. However, Ms. Gong also emphasized that the healthcare industry is professional, complex, and sensitive, and the application of new technologies must address challenges such as data security, privacy protection, and ethics.
“Data security and privacy protection are fundamental to the development of AI technology and medical big data technology. We must ensure that all stakeholders are satisfied with compliance, security, accessibility, and privacy protection.”
“AI technology still has a long way to go.” She called on policymakers, healthcare institutions, and technology companies to work together to realize the immense potential of healthcare data. Ms. Gong highlighted that building trust is key, and enhancing data operability is essential to fully unleash the power of data. “It’s not just about better data quality; it’s about a better future for health.”

View original content:https://www.prnewswire.co.uk/news-releases/transforming-healthcare-with-ai-yidu-techs-gong-rujing-at-summer-davos-302186561.html

Continue Reading

Artificial Intelligence

Yidu Tech’s FY2024 results: existing business achieves first full-year profit on adjusted EBITDA

Published

on

yidu-tech’s-fy2024-results:-existing-business-achieves-first-full-year-profit-on-adjusted-ebitda

HONG KONG, July 1, 2024 /PRNewswire/ — On June 27, 2024, Yidu Tech Inc. (the ”Company” or ”Yidu Tech”) (2158.HK), a leader in China’s AI medical industry, announced its results for the 2024 fiscal year. During the reporting period, the Company recorded revenue of RMB 807.1 million. Gross profit margin in FY2024 increased to 42.1% from 34.1% in FY2023, representing an increase of 8 percentage points, hitting a record high. Adjusted net loss narrowed from RMB 448.7 million in FY2023 to RMB158.1 million, down 64.8% year-on-year. The management of Yidu Tech said at the annual results conference the next day that excluding strategic investments in proprietary large language model, non-cash items, and non-operating items, the adjusted EBITDA for our current business has achieved profit, moving from a RMB 327 million loss to a profit of RMB 31.1 million for the first time this fiscal year.

Management added that as of market close on June 27, the Company’s P/B ratio has decreased to 1.06. Not including the valuation of its domestic and international businesses, its market value is still lower than its fund reserves on hand. As such, management believes that the Company’s share price is still severely undervalued. Notably, renowned sovereign fund BIA has continually increased its shareholding of Yidu Tech by 21.50% over the past two months. The management is confident in the Company’s long-term growth potential and hopes to continually create innovative technologies and increase returns to its shareholders.
In FY2024, Yidu Tech focused on its core business, improving internal operating efficiency and earning quality. Among its earnings, revenue from its big data platform and solutions segment reached RMB 313.6 million, an increase of 41.4% year-on-year. Revenue from its life science solutions segment reached RMB 324.0 million, up 28.1% year-on-year and the gross margin increased by 14.6 percentage points to a historical high of 32.1%. Revenue from its health management platform and solutions segment reached RMB 169.5 million, and the gross profit margin of this segment was 58.1%, representing a year-on-year increase of 17.4 percentage points.
During the reporting period, the Company has continued the development and training of large language model in the medical vertical field based on 500 billion fine-trained Tokens, with model training for 6B, 13B, and 70B parameters completed.

View original content:https://www.prnewswire.co.uk/news-releases/yidu-techs-fy2024-results-existing-business-achieves-first-full-year-profit-on-adjusted-ebitda-302185986.html

Continue Reading

Artificial Intelligence

Lucinity’s AI Innovation Recognized at Microsoft’s Prestigious Global Partner Awards 2024

Published

on

lucinity’s-ai-innovation-recognized-at-microsoft’s-prestigious-global-partner-awards-2024

REYKJAVIK, Iceland, June 28, 2024 /PRNewswire/ — Lucinity has been recognized as a finalist in the AI Innovation category at the prestigious Microsoft Global Partner Awards 2024, recognizing its breakthrough AI solution and contribution to financial security through its collaboration with Microsoft. 

Lucinity beat more than 4,700 companies to be named a finalist at the annual Microsoft Global Partner Awards, which highlights Lucinity’s achievements as a Microsoft partner in optimizing business processes, improving customer experiences, and opening new pathways for digital transformation.
This achievement comes in addition to winning two prestigious awards at Microsoft Partner Awards 2024 last month, including Partner of the Year – Iceland, and the Sustainability and Social Impact award.
The accolade recognizes Lucinity’s significant advancements in AI for financial crime operations, particularly through their AI-powered copilot, Luci. This innovative solution utilizes Microsoft Azure OpenAI technology to integrate advanced generative AI into financial crime investigations and regulatory compliance, optimizing processes and saving significant time and resources for financial institutions.
The Lucinity platform streamlines compliance, provides instant insights, and reduces typical investigation times from three hours to just 30 minutes. The technology can also save financial institutions an estimated $100 million in productivity savings, as well as savings in training and recruitment.
Microsoft comments on Lucinity’s award recognition, saying “Financial crime profoundly impacts our global community, with far-reaching economic, security, and social implications. It can harm a country’s reputation and increase exposure to criminal activities, emphasizing the critical need for robust anti-money laundering initiatives and persistent vigilance. Lucinity, with their innovative AI solutions, has really tried to combat this huge global challenge. They use ‘Human AI’ to enhance financial crime prevention, combining AI with human expertise for efficient, user-friendly solutions. Additionally, Lucinity has developed a tool called Luci, an AI-powered copilot that helps transform financial crime prevention from a process that took hours to one that takes minutes.”
“Being recognized as a finalist at the Microsoft Global Partner Awards is  validation of our impactful collaboration with Microsoft in financial crime operations. Our partnership has been pivotal for our innovations, enabling us to use Azure OpenAI to bring tools like Luci to life and deliver impactful results for our clients,” says Guðmundur Kristjánsson, Founder & CEO of Lucinity.
Contact:Name: Celina PabloEmail: [email protected]: +354 792 4321
Logo: https://mma.prnewswire.com/media/2208676/4669079/Lucinity_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/lucinitys-ai-innovation-recognized-at-microsofts-prestigious-global-partner-awards-2024-302186091.html

Continue Reading

Trending